Invivyd Inc (NAS:IVVD)
$ 0.51 -0.0204 (-3.85%) Market Cap: 61.00 Mil Enterprise Value: -44.23 Mil PE Ratio: 0 PB Ratio: 0.73 GF Score: 30/100

Invivyd Inc at Guggenheim Securities Inflammation & Immunology Conference Transcript

Nov 07, 2023 / 08:50PM GMT
Release Date Price: $1.49 (-1.32%)
Evan Wang
Guggenheim Securities LLC - Analyst

Great. Good afternoon, everyone. Thanks for joining us for this fireside chat with Invivyd. I'm Evan Wang, one of our biopharma team's senior analysts, and I'm joined by Invivyd's CEO, Dave Hering.

Dave Hering
Invivyd, Inc. - CEO & Director

Good to be here.

Questions & Answers

Evan Wang
Guggenheim Securities LLC - Analyst

Yeah. Great to have you. Dave, just to set the stage for those unfamiliar, can you just give a brief introduction on Invivyd and help frame the unmet need with COVID?

Dave Hering
Invivyd, Inc. - CEO & Director

Yeah, course. So we're a biopharmaceutical company focused on monoclonal antibody therapies, really targeting people with immune-compromised populations, vulnerable populations, people who aren't going to get all the protection they need from a vaccine or other therapy. Targeting this in a serial platform way to be able to continuously provide these products and really focused

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot